These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21691037)

  • 21. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
    Khan AH; Imig JD
    Am J Hypertens; 2011 Jul; 24(7):816-21. PubMed ID: 21415842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A
    Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of two treatment combinations of hypertension in very elderly patients.
    Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
    Arch Gerontol Geriatr; 2009; 48(3):401-5. PubMed ID: 18457886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Irbesartan: a new possibility in the treatment of hypertension].
    Rapi J
    Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
    Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
    Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
    Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irbesartan substitution for valsartan or losartan in treating hypertension.
    Graham MR; Allcock NM
    Ann Pharmacother; 2002 Dec; 36(12):1840-4. PubMed ID: 12452741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
    Brosnan MJ; Hamilton CA; Graham D; Lygate CA; Jardine E; Dominiczak AF
    J Hypertens; 2002 Feb; 20(2):281-6. PubMed ID: 11821713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats.
    Muñoz MC; Giani JF; Dominici FP; Turyn D; Toblli JE
    J Hypertens; 2009 Dec; 27(12):2409-20. PubMed ID: 19901849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
    Fujita K; Yoneda M; Wada K; Mawatari H; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Saito S; Iwasaki T; Terauchi Y; Nakajima A
    Dig Dis Sci; 2007 Dec; 52(12):3455-64. PubMed ID: 17410441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Kusunoki H; Taniyama Y; Rakugi H; Morishita R
    J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.
    Negro R; Formoso G; Hassan H
    J Endocrinol Invest; 2006 Dec; 29(11):957-61. PubMed ID: 17259791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Up-regulation of PPARgamma in myocardial infarction.
    Fliegner D; Westermann D; Riad A; Schubert C; Becher E; Fielitz J; Tschöpe C; Regitz-Zagrosek V
    Eur J Heart Fail; 2008 Jan; 10(1):30-8. PubMed ID: 18162196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
    Chow L; De Gasparo M; Levens N
    Eur J Pharmacol; 1995 Aug; 282(1-3):77-86. PubMed ID: 7498292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.
    Kotridis P; Kokkas B; Karamouzis M; Sakadamis G; Kanonidis I; Dadous G; Karantona C; Gouli O; Karadoumanis J; Papadopoulos PC; Papadopoulos CL
    Blood Press; 2002; 11(2):91-4. PubMed ID: 12035877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.